TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03061331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Active Drug
Study: NCT02567032
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT04177342
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
Study: NCT02605694
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)
Study: NCT02074137
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT01955837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study: NCT02548364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control group
Study: NCT02440399
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02440399
Drug: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01438944
Drug: Nicabate 21mg transdermal NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
Study: NCT00470067
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01301001
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 capsules am and 3 capsules pm
Study: NCT02635789
Drug: NPC-12G gel
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-12G gel is administered topically twice a day for 12 weeks
Study: NCT02635789
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-12G gel placebo is administered topically twice a day for 12 weeks
Study: NCT03043820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets identical in form and color to intervention.
Study: NCT01279187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ug per day, self administered injection, for 7 weeks
Study: NCT03954938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
Study: NCT00781664
Drug: AN2718
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2718 Cream SF, 0.3%, Daily for up to 21 days
Study: NCT00781664
Drug: AN2718
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2718 Cream SF, 1%, Daily for up to 21 days
Study: NCT00781664
Drug: AN2718
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2718 Gel, 1.5%, Daily for up to 21 days
Study: NCT00781664
Drug: AN2718
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2718 Gel, 2.5%, Daily for up to 21 days
Study: NCT00781664
Drug: AN2718
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2718 Gel, 5%, Daily for up to 21 days
Study: NCT00781664
Drug: AN2718
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2718 Gel, 7.5%, Daily for up to 21 days
Study: NCT01862965
Drug: PredEver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstline treatment with prednisone and Everolimus
Study: NCT04405843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
Study: NCT02884180
Drug: Saline isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 6 ml of isotonic saline given after start of anaesthesia
Study: NCT00003151
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003151
Drug: tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01286935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01096186
Drug: IPX066 95 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.75 - 95 mg CD-LD capsules
Study: NCT01096186
Drug: IPX066 145 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36.25 - 145 mg CD-LD capsules
Study: NCT01096186
Drug: IPX066 195 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48.75 - 195 mg CD-LD capsules
Study: NCT01096186
Drug: IPX066 245 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 61.25 - 245 mg CD-LD capsules
Study: NCT01367756
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses, Days 10-16
Study: NCT01367756
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses, Days 10-16
Study: NCT00143520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01104337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment consisted of two matching placebo tablets three times a day.
Study: NCT00790660
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00790660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00629642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02656342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted to have no enhancing effect
Study: NCT00512083
Drug: AS1411
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
Study: NCT02046200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT03156452
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg tablets for oral administration
Study: NCT00005922
Drug: Dose control for Arm B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
Study: NCT03559400
Drug: local gentamicin injection
Normalized name: gentamicin Injection
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
Study: NCT02417337
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02417337
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02417337
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03400943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was administered to group B1 and B2.
Study: NCT01623284
Drug: F-18 FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
Study: NCT02622594
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002461
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00513474
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
Study: NCT02975700
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day (400 mg in the morning and 600 mg in the evening)
Study: NCT02416388
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11
Study: NCT02416388
Drug: Mycophenolic acid (MPA)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Study: NCT02784444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01316900
Drug: GSK573719/GW642444 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125/25 mcg once-daily
Study: NCT01316900
Drug: GSK573719/GW642444 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5/26 mcg once-daily
Study: NCT01316900
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mcg once-daily
Study: NCT02713841
Drug: inhaled human insulin (INH)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human insulin administered with Adagio-01 inhaler device
Study: NCT00289900
Drug: MK-0524A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00289900
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02186171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once a month.
Study: NCT04746183
Drug: CST-2: EIDD-2801
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.
Study: NCT04746183
Drug: CST-2: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
Study: NCT04746183
Drug: CST-5: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
Study: NCT04746183
Drug: ALG-097558
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG-097558 600 mg Twice a day (BD) for 5 days
Study: NCT04746183
Drug: NHS standard of care as per COVID-19 treatment guidelines
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS standard of care as per COVID-19 treatment guidelines
Study: NCT00954135
Drug: letrozolo+cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
Study: NCT00954135
Drug: letrozolo+sorafenib+cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months
Study: NCT01426555
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg IV single dose
Study: NCT00834587
Drug: 5 mg/500 mg METAGLIP™ Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 5 mg/500 mg, single-dose non-fasting
Study: NCT00513474
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
Study: NCT02434614
Drug: Docetaxel,Cisplatin,Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
Study: NCT00851136
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00851136
Drug: PRO95780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT03220555
Drug: EMLAPATCH (lidocaine, prilocaine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
Study: NCT04098744
Drug: Placebo vaginal insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for artesunate vaginal inserts
Study: NCT04597333
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone vaginal insert.
Study: NCT02137356
Drug: standard dose capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
Study: NCT01144351
Drug: ELND002
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01144351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01324466
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Study: NCT03517020
Drug: Forest Pharmaceuticals Inc's Bystolic Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03173508
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT00443287
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03479346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT03949231
Drug: PD1/PDL1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
Study: NCT01123525
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
Study: NCT00657501
Drug: testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily transdermal gel, 300 mcg
Study: NCT00657501
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily transdermal placebo gel
Study: NCT01990352
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
Study: NCT01292473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied lyophilized in vials.
Study: NCT03682393
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
Study: NCT03682393
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
Study: NCT01429935
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capsules of Ibuprofen 400 mg, every 6 hours for 5 days
Study: NCT01881633
Drug: ISU302
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01881633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01433978
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study: NCT03395912
Drug: Intervention
Normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
Study: NCT01296113
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total
Study: NCT00440739
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg
Study: NCT00440739
Drug: etoricoxib, flavoxate
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg once and flavoxate 200 mg 3 times
Study: NCT00440739
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once and placebo 3 times
Study: NCT02551809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT04250363
Drug: Palcebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
Study: NCT04250363
Drug: M5717 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 30 mg single oral dose of M5717 capsule on Day 1.
Study: NCT04250363
Drug: M5717 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 1.
Study: NCT04250363
Drug: M5717 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 80 mg single oral dose of M5717 capsule on Day 1.
Study: NCT04250363
Drug: M5717 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 1.
Study: NCT04250363
Drug: M5717 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 1.
Study: NCT04250363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
Study: NCT04250363
Drug: M5717 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 5.
Study: NCT04250363
Drug: M5717 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 5.
Study: NCT04250363
Drug: M5717 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Study: NCT01857115
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04614779
Drug: CN128 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelator, oral tablets
Study: NCT00949663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1% human albumin in normal saline
Study: NCT01401075
Drug: mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
Study: NCT03116087
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mcg testosterone patches or placebo applied twice weekly
Study: NCT03116087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch
Study: NCT04590183
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times a day
Study: NCT00290758
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02681432
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
Study: NCT03178942
Drug: Elimite™ Cream (permethrin) 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin Cream 5%
Study: NCT01429623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00414609
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.